The biotech stock's price-to-earnings-to-growth (PEG) ratio is a super-low 0.58, according to the London Stock Exchange Group (LSEG). Any PEG ratio below 1.0 is viewed as an attractive valuation.

The 12-month price targets, analyzed by analysts, offer insights with an average target of $508.38, a high estimate of ...

Industry insiders hope the Fed’s decision to cut rates for the first time in years will boost biotech investment. But the long-awaited move won’t cure all that ails the sector, others cautioned.

It’s been almost a year since the Food and Drug Administration approved the first genetic treatments for sickle cell disease.